Interim Stay On Order Suspending Manufacture Of 14 Patanjali Drugs

New Delhi: An interim stay was put on Friday on the implementation of an order suspending manufacturing licences of more than a dozen medicines of Patanjali Ayurved Ltd and Divya Pharmacy. The interim stay is being imposed with immediate effect on the basis of a preliminary inquiry report of a high level committee, Pankaj Kumar Pandey, Secretary Ayush, Uttarakhand government said in an order.

“The order of the suspension is illegal and should not have been passed by the licensing authority in the manner it has been passed,” the committee looking into the matter said in its report.

The firms had challenged the last month’s suspension order of the Uttarakhand state licensing authority.

“Since the licence has been cancelled without following the procedure established by law, the committee is submitting its report to the government of Uttarakhand for appropriate decision,” it said.

The State Licensing Authority, Ayurvedic and Unani Services had suspended the manufacturing licence of 14 Patanjali products last month under Drugs and Cosmetics Act 1945 and Drugs and Magic Remedies (Objectionable Advertisements) Act 1954.

The medicines whose manufacturing licence had been suspended included Swasari Gold, Swasari Vati, Bronchom, Swasari Pravahi, Swasari Avaleh, Mukta Vati Extra Power, Lipidom, BP Grit, Madhugrit, Madhunashini Vati Extra Power, Livamrit Advance, Livogrit, Eyegrit Gold and Patanjali Drishti Eyedrop.

Related Posts

  • Pharma
  • June 18, 2025
  • 90 views
Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharmaceuticals said that the United States’ Food and Drug Administration (FDA) has concluded inspection of its manufacturing facility in Monroe, North Carolina. Glenmark Pharmaceuticals said that the United States’…

  • Pharma
  • June 18, 2025
  • 79 views
ED conducts searches across six States in drug trafficking case

The Enforcement Directorate on Tuesday conducted searches at 15 locations, including the premises of five pharmaceutical companies, across six States in connection with a drug trafficking case registered in Punjab.…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

Glenmark Pharma: FDA concludes inspection at US facility, issues five observations

ED conducts searches across six States in drug trafficking case

ED conducts searches across six States in drug trafficking case

Gurugram: Teen dies after ‘friendly’ blow to chest; hospital role under scanner

Gurugram: Teen dies after ‘friendly’ blow to chest; hospital role under scanner

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base

Biocon launches Rs 4,500-crore QIP; to issue 11.6% of equity base